FY2025 EPS Estimates for ADMA Biologics Boosted by Analyst

ADMA Biologics, Inc. (NASDAQ:ADMA) – Investment analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for ADMA Biologics in a research report issued on Thursday, March 20th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will earn $0.73 per share for the year, up from their prior forecast of $0.70. Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share.

ADMA Biologics Trading Up 0.8 %

NASDAQ:ADMA opened at $19.80 on Friday. The company’s 50 day moving average price is $16.76 and its 200-day moving average price is $18.04. ADMA Biologics has a 52 week low of $5.90 and a 52 week high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of 70.71 and a beta of 0.60.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in ADMA Biologics by 1.3% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock worth $865,000 after purchasing an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock worth $954,000 after acquiring an additional 700 shares during the period. Summit Investment Advisors Inc. raised its position in ADMA Biologics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company’s stock worth $404,000 after acquiring an additional 746 shares during the period. Mutual of America Capital Management LLC raised its position in ADMA Biologics by 2.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock worth $614,000 after acquiring an additional 751 shares during the period. Finally, Maryland State Retirement & Pension System raised its position in ADMA Biologics by 1.1% in the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock worth $1,365,000 after acquiring an additional 897 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.